Olanzapine pamoate: a stick in time?

Olanzapine pamoate, a long‐acting depot preparation of olanzapine, is being evaluated by regulatory agencies for the treatment of schizophrenia. Clinical trial information was accessed by on‐line query of http://www.pubmed.gov, http://www.clinicaltrials.gov and http://www.fda.gov, along with an examination of poster presentations at scientific meetings held in 2008.

[1]  L. Hranov,et al.  Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial , 2008, The Lancet.

[2]  P. Weiden,et al.  Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. , 2004, Psychiatric services.

[3]  M. Valenstein,et al.  Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. , 2006, The Journal of clinical psychiatry.

[4]  M. Byerly,et al.  Antipsychotic medication adherence in schizophrenia. , 2007, The Psychiatric clinics of North America.

[5]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[6]  L. Citrome,et al.  Compelling or irrelevant? Using number needed to treat can help decide , 2008, Acta psychiatrica Scandinavica.

[7]  J. Lauriello,et al.  An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. , 2008, The Journal of clinical psychiatry.

[8]  I. Glick,et al.  A meta-analysis of the efficacy of second-generation antipsychotics , 2003, Schizophrenia Research.

[9]  L. Citrome,et al.  Olanzapine: review of safety 2008 , 2008 .

[10]  S. Soumerai,et al.  A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. , 2008, The Journal of clinical psychiatry.

[11]  Leslie Citrome,et al.  Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks , 2008, Expert review of neurotherapeutics.

[12]  S. Kapur,et al.  D2 Receptor Occupancy of Olanzapine Pamoate Depot Using Positron Emission Tomography: An Open-label Study in Patients with Schizophrenia , 2008, Neuropsychopharmacology.

[13]  G. Morken,et al.  Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia , 2008, BMC psychiatry.

[14]  L. Citrome,et al.  Do guidelines for severe mental illness promote physical health and well-being? , 2005, Journal of psychopharmacology.